<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01952483</url>
  </required_header>
  <id_info>
    <org_study_id>IM.SK1.04</org_study_id>
    <nct_id>NCT01952483</nct_id>
  </id_info>
  <brief_title>Effect of Vitamin D Replacement on Immune Function and Cognition in MS Patients</brief_title>
  <official_title>Effect of Vitamin D Replacement on Immune Function and Cognition in MS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American University of Beirut Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American University of Beirut Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessing the immune activation in MS patients deficient in Vitamin D and whether Vitamin D
      supplementation reverse the immune activation

      Evaluating whether Vitamin D deficiency result in lower cognitive performance in MS patients
      and the effect of Vitamin D supplementation on reversing the cognitive impairment?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will compare the immune responses in patients with Vitamin D deficiency (serum level
      &lt;20ng/ml) to those of patients with normal Vitamin D (serum level &gt;35 ng/ml). We will focus
      on proliferation and cytokine production to myelin basic protein (MBP) and myelin
      oligodendrocyte glycoprotein (MOG) peptides and on the percentage of Th1 (IFN gamma producing
      cells) and Th17 (IL-17 producing cells) during in vitro polarization assays. Our hypothesis
      is that patients with low Vitamin D have increase proliferation to MBP and MOG and increased
      production of pro-inflammatory cytokines (IFN gamma and IL-17) and that Vitamin D
      supplementation will decrease this pro-inflammatory profile.

      We will measure cognitive performance in patients with Vitamin D deficiency (serum level
      &lt;20ng/ml) compared to those of patients with normal Vitamin D (serum level &gt;35 ng/ml) after
      adjusting for educational levels and disease duration. We hypothesize that low Vitamin D has
      a negative effect on cognitive performance and that Vitamin D supplementation will improve
      cognitive function.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">May 1, 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Is there evidence of immune activation in MS patients deficient in Vitamin D and does Vitamin D supplementation reverse the immune activation?</measure>
    <time_frame>3months</time_frame>
    <description>We will compare the immune responses in patients with Vitamin D deficiency (serum level &lt;20ng/ml) to those of patients with normal Vitamin D (serum level &gt;35 µg/ml). We will focus on proliferation and cytokine production to myelin basic protein (MBP) and myelin oligodendrocyte glycoprotein (MOG) peptides and on the percentage of Th1 (IFN gamma producing cells) and Th17 (IL-17 producing cells) during in vitro polarization assays. Our hypothesis is that patients with low Vitamin D have increase proliferation to MBP and MOG and increased production of pro-inflammatory cytokines (IFN gamma and IL-17) and that Vitamin D supplementation will decrease this pro-inflammatory profile.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Does Vitamin D deficiency result in lower cognitive performance in MS patients and does Vitamin D supplementation reverse the cognitive impairment?</measure>
    <time_frame>3 months</time_frame>
    <description>We will measure cognitive performance in patients with Vitamin D deficiency (serum level &lt;20ng/ml) compared to those of patients with normal Vitamin D (serum level &gt;35 ng/ml) after adjusting for educational levels and disease duration. We hypothesize that low Vitamin D has a negative effect on cognitive performance and that Vitamin D supplementation will improve cognitive function.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">108</enrollment>
  <condition>Multiple Sclerosis (MS)</condition>
  <arm_group>
    <arm_group_label>vitamin D deficient,</arm_group_label>
    <description>Vitamin D deficiency (serum level &lt;20ng/ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D normal</arm_group_label>
    <description>Serum level &gt;35 ng/ml</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      We will focus on proliferation and cytokine production to myelin basic protein (MBP) and
      myelin oligodendrocyte glycoprotein (MOG) peptides and on the percentage of Th1 (IFN gamma
      producing cells) and Th17 (IL-17 producing cells) during in vitro polarization assays
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Group 1: low vitamin D (less than 25 ng/ml) Group 2: normal vitamin D level (greater than
        35 ng/ ml)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Definite diagnosis of Multiple Sclerosis following the revised McDonald MS diagnostic
             criteria

          2. Male and Female Aged 18 and above

          3. On interferon-β treatment (Rebif®, Avonex®, or Betaseron®)

          4. No signs of active inflammation or attack or new lesions on MRI

        Exclusion Criteria:

          1. Treatment with immune modulating/ suppressive drugs other than IFN-b within 6 weeks
             prior to enrolment

          2. Pregnancy

          3. Hypercalcemia

          4. eglomerular filtration rate&lt;60

          5. History of primary hyperparathyroidism, hypercalcemia, renal dysfunction, cardiac
             disease, malignancy, or granulomatous disease

          6. The occurrence of an exacerbation (defined as an episode of neurologic dysfunction
             lasting at least 24 hours) within 4 weeks of enrollment

          7. History of dementia or related disorders

          8. History of traumatic brain injury

          9. Diagnosis of epilepsy or history of seizure

         10. Diagnosis of psychiatric disease, substance abuse/dependence, alcohol abuse/dependence

         11. Currently, on any of the following medications Lithium, or Thiazide diuretics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samia J Khoury, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>AUBMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AUBMC Multiple Sclerosis Center</name>
      <address>
        <city>Beirut</city>
        <state>Riad El Solh</state>
        <zip>11-0236</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <reference>
    <citation>Khoo AL, Joosten I, Michels M, Woestenenk R, Preijers F, He XH, Netea MG, van der Ven AJ, Koenen HJ. 1,25-Dihydroxyvitamin D3 inhibits proliferation but not the suppressive function of regulatory T cells in the absence of antigen-presenting cells. Immunology. 2011 Dec;134(4):459-68. doi: 10.1111/j.1365-2567.2011.03507.x.</citation>
    <PMID>22044285</PMID>
  </reference>
  <reference>
    <citation>Zivadinov R, Sepcic J, Nasuelli D, De Masi R, Bragadin LM, Tommasi MA, Zambito-Marsala S, Moretti R, Bratina A, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001 Jun;70(6):773-80.</citation>
    <PMID>11385012</PMID>
  </reference>
  <reference>
    <citation>Adorini L, Penna G, Giarratana N, Roncari A, Amuchastegui S, Daniel KC, Uskokovic M. Dendritic cells as key targets for immunomodulation by Vitamin D receptor ligands. J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):437-41. Review.</citation>
    <PMID>15225816</PMID>
  </reference>
  <reference>
    <citation>Przybelski RJ, Binkley NC. Is vitamin D important for preserving cognition? A positive correlation of serum 25-hydroxyvitamin D concentration with cognitive function. Arch Biochem Biophys. 2007 Apr 15;460(2):202-5. Epub 2007 Jan 8.</citation>
    <PMID>17258168</PMID>
  </reference>
  <reference>
    <citation>Barake M, Daher RT, Salti I, Cortas NK, Al-Shaar L, Habib RH, Fuleihan Gel-H. 25-hydroxyvitamin D assay variations and impact on clinical decision making. J Clin Endocrinol Metab. 2012 Mar;97(3):835-43. doi: 10.1210/jc.2011-2584. Epub 2012 Jan 11.</citation>
    <PMID>22238386</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2013</study_first_submitted>
  <study_first_submitted_qc>September 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2013</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>American University of Beirut Medical Center</investigator_affiliation>
    <investigator_full_name>Samia Khoury</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis (MS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

